Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash from Financing Activities (2016 - 2025)

Conmed (CNMD) has disclosed Cash from Financing Activities for 16 consecutive years, with -$37.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 26.83% year-over-year to -$37.4 million, compared with a TTM value of -$135.8 million through Dec 2025, up 10.05%, and an annual FY2025 reading of -$135.8 million, up 10.05% over the prior year.
  • Cash from Financing Activities was -$37.4 million for Q4 2025 at Conmed, up from -$43.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $159.1 million in Q2 2022 and bottomed at -$58.8 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is -$13.7 million, with a median of -$27.5 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities skyrocketed 820.17% in 2022, then crashed 610.34% in 2023.
  • Year by year, Cash from Financing Activities stood at -$40.8 million in 2021, then surged by 128.23% to $11.5 million in 2022, then plummeted by 610.34% to -$58.8 million in 2023, then increased by 13.1% to -$51.1 million in 2024, then increased by 26.83% to -$37.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CNMD at -$37.4 million in Q4 2025, -$43.5 million in Q3 2025, and -$26.5 million in Q2 2025.